Format

Send to

Choose Destination
J Oncol Pharm Pract. 2016 Apr;22(2):325-31. doi: 10.1177/1078155214560921. Epub 2014 Dec 7.

Topical cidofovir-induced acute kidney injury in two severely immunocompromised patients with refractory multidrug-resistant herpes simplex virus infections.

Author information

1
UC San Diego Skaggs School of Pharmacy & Pharmaceutical Sciences, La Jolla, CA, USA (At the time of submission, Ila M Saunders was a Clinical Pharmacy Specialist in the Division of Pharmacy at The University of Texas MD Anderson Cancer Center, Houston, TX, USA) isaunders@ucsd.edu.
2
Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
3
Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
4
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
5
Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Abstract

Cidofovir, a nucleoside analog of deoxycytidine monophosphate, is a water-soluble polar molecule that exhibits antiviral activity against a broad range of DNA viruses. Cidofovir for injection is approved for the treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. The safety and efficacy of topical cidofovir has been described in a limited number of patients. We present two cases of multidrug-resistant herpes simplex virus infections that responded to topical cidofovir therapy yet resulted in irreversible acute kidney injury.

KEYWORDS:

Topical cidofovir; acute kidney injury; herpes simplex virus; immmunocompromised

PMID:
25488905
DOI:
10.1177/1078155214560921
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center